Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Tango Therapeutics, Inc.
A clinical-stage biotechnology company developing precision cancer medicines, Tango Therapeutics uses a CRISPR-based platform to find genetic "weak spots" in tumor cells and build drugs that attack them. Founded in 2017 in the Boston area, the company takes its name from "synthetic lethality," a biological tango where two gene flaws together kill a cell, while either alone does not. Its lead drug candidate, vopimetostat, is being tested against pancreatic cancer.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders
2.02 Results of Operations and Financial Condition · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits